It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Oncogene-induced DNA replication stress (RS) and consequent pathogenic R-loop formation are known to impede S phase progression. Nonetheless, cancer cells continuously proliferate under such high-stressed conditions through incompletely understood mechanisms. Here, we report taurine upregulated gene 1 (TUG1) long noncoding RNA (lncRNA), which is highly expressed in many types of cancers, as an important regulator of intrinsic R-loop in cancer cells. Under RS conditions, TUG1 is rapidly upregulated via activation of the ATR-CHK1 signaling pathway, interacts with RPA and DHX9, and engages in resolving R-loops at certain loci, particularly at the CA repeat microsatellite loci. Depletion of TUG1 leads to overabundant R-loops and enhanced RS, leading to substantial inhibition of tumor growth. Our data reveal a role of TUG1 as molecule important for resolving R-loop accumulation in cancer cells and suggest targeting TUG1 as a potent therapeutic approach for cancer treatment.
Proliferation of cancer cells leads to replication stress through incompletely understood mechanisms. Here, the authors show that the long noncoding RNA TUG1 resolves R-loops and reduces replication stress in cancer cells.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
















1 Nagoya University Graduate School of Medicine, Division of Cancer Biology, Nagoya, Japan (GRID:grid.27476.30) (ISNI:0000 0001 0943 978X)
2 Nagoya University Graduate School of Medicine, Division of Cancer Biology, Nagoya, Japan (GRID:grid.27476.30) (ISNI:0000 0001 0943 978X); Hamamatsu University School of Medicine, Laboratory Animal Facilities and Services, Preeminent Medical Photonics Education and Research Center, Hamamatsu, Japan (GRID:grid.505613.4) (ISNI:0000 0000 8937 6696)
3 Nagoya University Graduate School of Medicine, Division of Molecular Oncology, Nagoya, Japan (GRID:grid.27476.30) (ISNI:0000 0001 0943 978X)
4 Nagoya University Graduate School of Medicine, Department of Neurosurgery, Nagoya, Japan (GRID:grid.27476.30) (ISNI:0000 0001 0943 978X)
5 Nagoya University Graduate School of Medicine, Division of Cancer Biology, Nagoya, Japan (GRID:grid.27476.30) (ISNI:0000 0001 0943 978X); Nagoya University Graduate School of Medicine, Department of Neurosurgery, Nagoya, Japan (GRID:grid.27476.30) (ISNI:0000 0001 0943 978X)
6 Kanagawa Cancer Center Research Institute, Molecular Pathology and Genetics Division, Yokohama, Japan (GRID:grid.414944.8) (ISNI:0000 0004 0629 2905)
7 International University of Health and Welfare, School of Health Sciences at Narita, Narita, Japan (GRID:grid.411731.1) (ISNI:0000 0004 0531 3030)
8 Japanese Foundation for Cancer Research, Department of Cell Biology, Koto-ku, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131)
9 The University of Tokyo, Department of Materials Engineering, Graduate School of Engineering, Bunkyo-ku, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
10 Kawasaki Institute of Industrial Promotion, Innovation Center of NanoMedicine, Kawasaki-ku, Japan (GRID:grid.493442.c) (ISNI:0000 0004 5936 3316); The University of Tokyo, Institute for Future Initiatives, Bunkyo-ku, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
11 Nagoya University Graduate School of Medicine, Division of Molecular Oncology, Nagoya, Japan (GRID:grid.27476.30) (ISNI:0000 0001 0943 978X); Tokai National Higher Education and Research System, Institute for Glyco-core Research (iGCORE), Nagoya, Japan (GRID:grid.27476.30)
12 Nagoya University Graduate School of Medicine, Division of Cancer Biology, Nagoya, Japan (GRID:grid.27476.30) (ISNI:0000 0001 0943 978X); Tokai National Higher Education and Research System, Institute for Glyco-core Research (iGCORE), Nagoya, Japan (GRID:grid.27476.30)